Blood cancers

Ponatinib gets additional PBS indication for ALL

The tyrosine kinase inhibitor ponatinib is now listed on the PBS for treatment of patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). Ponatinib has an Authority Required listing from 1 September for management of patients with Ph+ ALL who have failed or are intolerant to dasatinib but do not have the ...

Already a member?

Login to keep reading.

© 2021 the limbic